Elevation Oncology, Inc. (ELEV) Social Stream
ELEVATION ONCOLOGY INC (ELEV) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering ELEVATION ONCOLOGY INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-15 | 4 | $27 | $20 | $23.666 | $0.592 | 3897.64% |
| 2021-11-17 | 4 | $27 | $20 | $22.666 | $0.592 | 3728.72% |
| 2021-12-27 | 5 | $27 | $12 | $20 | $0.592 | 3278.38% |
| 2022-03-04 | 5 | $27 | $11 | $17.75 | $0.592 | 2898.31% |
| 2022-03-08 | 5 | $21 | $11 | $14.25 | $0.592 | 2307.09% |
| 2022-05-05 | 4 | $21 | $11 | $15 | $0.592 | 2433.78% |
| 2022-05-06 | 4 | $15 | $11 | $13 | $0.592 | 2095.95% |
| 2022-05-09 | 4 | $15 | $11 | $12.333 | $0.592 | 1983.28% |
| 2022-07-27 | 1 | $15 | $11 | $12.333 | $0.592 | 1983.28% |
| 2022-08-08 | 4 | $11 | $8 | $9.5 | $0.592 | 1504.73% |
| 2022-10-26 | 4 | $11 | $7.5 | $8.833 | $0.592 | 1392.06% |
| 2022-11-03 | 4 | $11 | $6 | $8.166 | $0.592 | 1279.39% |
| 2022-11-07 | 4 | $7.5 | $2 | $5.166 | $0.592 | 772.64% |
| 2023-01-09 | 4 | $7.5 | $1 | $4.833 | $0.592 | 716.39% |
| 2023-01-23 | 4 | $7.5 | $1 | $4.166 | $0.592 | 603.72% |
| 2023-05-15 | 3 | $7.5 | $4 | $5.5 | $0.592 | 829.05% |
| 2023-05-30 | 3 | $8 | $4 | $6.5 | $0.592 | 997.97% |
| 2023-08-03 | 3 | $8 | $5 | $6.5 | $0.592 | 997.97% |
| 2023-11-06 | 3 | $8 | $1.5 | $4.833 | $0.592 | 716.39% |
The Trend in the Analyst Price Target
ELEV's average price target has moved down $4 over the prior 14 months.
ELEV reports an average of 455.06% for its upside potential over the past 43 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-05-30 | 3 | 8 | 4.0 | 6.500 | 4.350 | 49.43% |
| 2023-06-05 | 3 | 8 | 6.0 | 7.166 | 2.650 | 170.42% |
| 2023-08-03 | 2 | 8 | 6.0 | 7.166 | 1.040 | 589.04% |
| 2023-09-29 | 3 | 8 | 1.5 | 4.833 | 0.663 | 628.96% |
| 2023-11-06 | 4 | 8 | 1.5 | 4.833 | 0.496 | 874.4% |
ELEV Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 3 | 0 | 0 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
Over the past 43 weeks, ELEV's average broker recommendation rating improved by 1.5.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In the context of all US stocks, ELEVATION ONCOLOGY INC's upside potential (average analyst target price relative to current price) is higher than 2642.76% of them.
- In the context of all US stocks, ELEVATION ONCOLOGY INC's number of analysts covering the stock is higher than 313.16% of them.
- To contextualize these metrics, consider that out of Healthcare stocks, ELEVATION ONCOLOGY INC's average analyst price target is greater than 502.63% of them.
- ELEVATION ONCOLOGY INC's variance in analysts' estimates is lower than -985.15% of Pharmaceutical Products stocks.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ELEVATION ONCOLOGY INC are GRPH, ABOS, and CADL.
View All Top Stocks by Price Target
What is the outlook for ELEV? Use POWR Ratings for clearer insight into price direction.